Current and historical daily PE Ratio for China Resources Boya Bio-pharmaceutical Group Co Ltd (
SZSE:300294
) from 2012 to May 01 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. China Resources Boya Bio-pharmaceutical Group stock (SZSE:300294) PE ratio as of May 01 2024 is 73.16.
More Details
China Resources Boya Bio-pharmaceutical Group Co Ltd (SZSE:300294) PE Ratio (TTM) Chart
China Resources Boya Bio-pharmaceutical Group Co Ltd (SZSE:300294) PE Ratio (TTM) Historical Data
View and export this data going back to 2012. Start your Free Trial
Total 1176
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| China Resources Boya Bio-pharmaceutical Group PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-01 | 73.2 | 2024-02-26 | 59.8 |
| 2024-04-30 | 73.2 | 2024-02-23 | 60.0 |
| 2024-04-29 | 74.0 | 2024-02-22 | 60.0 |
| 2024-04-26 | 72.7 | 2024-02-21 | 59.6 |
| 2024-04-25 | 73.0 | 2024-02-20 | 59.5 |
| 2024-04-24 | 73.7 | 2024-02-19 | 58.5 |
| 2024-04-23 | 72.5 | 2024-02-08 | 59.0 |
| 2024-04-22 | 73.3 | 2024-02-07 | 58.9 |
| 2024-04-19 | 73.6 | 2024-02-06 | 57.5 |
| 2024-04-18 | 72.1 | 2024-02-05 | 50.4 |
| 2024-04-17 | 72.2 | 2024-02-02 | 52.9 |
| 2024-04-16 | 71.9 | 2024-02-01 | 55.3 |
| 2024-04-15 | 71.2 | 2024-01-31 | 56.3 |
| 2024-04-12 | 69.7 | 2024-01-30 | 57.7 |
| 2024-04-11 | 70.4 | 2024-01-29 | 59.6 |
| 2024-04-10 | 67.9 | 2024-01-26 | 60.7 |
| 2024-04-09 | 69.8 | 2024-01-25 | 62.3 |
| 2024-04-08 | 69.9 | 2024-01-24 | 58.7 |
| 2024-04-03 | 71.7 | 2024-01-23 | 60.1 |
| 2024-04-02 | 68.8 | 2024-01-22 | 59.1 |
| 2024-04-01 | 67.0 | 2024-01-19 | 62.3 |
| 2024-03-29 | 66.8 | 2024-01-18 | 62.7 |
| 2024-03-28 | 64.6 | 2024-01-17 | 63.5 |
| 2024-03-27 | 59.6 | 2024-01-16 | 64.8 |
| 2024-03-26 | 58.3 | 2024-01-15 | 65.7 |
| 2024-03-25 | 57.2 | 2024-01-12 | 65.4 |
| 2024-03-22 | 57.4 | 2024-01-11 | 66.5 |
| 2024-03-21 | 58.7 | 2024-01-10 | 67.2 |
| 2024-03-20 | 60.1 | 2024-01-09 | 67.7 |
| 2024-03-19 | 59.8 | 2024-01-08 | 68.0 |
| 2024-03-18 | 60.8 | 2024-01-05 | 68.8 |
| 2024-03-15 | 60.0 | 2024-01-04 | 70.7 |
| 2024-03-14 | 59.4 | 2024-01-03 | 71.3 |
| 2024-03-13 | 61.2 | 2024-01-02 | 70.6 |
| 2024-03-12 | 61.7 | 2023-12-29 | 71.7 |
| 2024-03-11 | 60.1 | 2023-12-28 | 70.4 |
| 2024-03-08 | 58.8 | 2023-12-27 | 35.2 |
| 2024-03-07 | 58.4 | 2023-12-26 | 34.5 |
| 2024-03-06 | 60.1 | 2023-12-25 | 34.8 |
| 2024-03-05 | 61.2 | 2023-12-22 | 35.1 |
| 2024-03-04 | 61.8 | 2023-12-21 | 34.7 |
| 2024-03-01 | 61.5 | 2023-12-20 | 34.7 |
| 2024-02-29 | 61.2 | 2023-12-19 | 35.2 |
| 2024-02-28 | 59.9 | 2023-12-18 | 35.6 |
| 2024-02-27 | 60.7 | 2023-12-15 | 35.8 |
China Resources Boya Bio-pharmaceutical Group Co Ltd (SZSE:300294) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
China Resources Boya Bio-pharmaceutical Group Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE100001FF1
Share Class Description:
SZSE:300294: Class ACompare
Compare
Traded in other countries / regions
300294.China IPO Date
2012-03-08Description
China Resources Boya Bio-pharmaceutical Group Co Ltd is a China-based medical industry group that integrates biochemical drugs, chemical drugs, and active pharmaceutical ingredients. It is engaged in the provision of medical and health products and services. The product categories of the company include blood products, biochemical drugs, chemical medicines and others. Some of the company's blood products include human albumin, rabies immunoglobulin, intravenous human immunoglobulin and human fibrinogen.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers